Navigation Links
Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/11/2010

BEDMINSTER, N.J., Nov. 11, 2010 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that Jerry Wisler, President and Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference at the St. Regis hotel in New York City on November 17, 2010 at  1:15pm Eastern time.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  The lead product candidate is Epanova, an Omega 3 fatty acid compound preparing to enter Phase III clinical development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL).  Future planned clinical trials for Epanova include patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy.  Omthera holds worldwide rights to Epanova.   For more information, please visit www.omthera.com.Media ContactRx Communications Group, LLCEric GoldmanVice President, Public Relations917-322-2563egoldman@rxir.com
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015  Research ... addition of the "An Introduction to the ... 2015)" conference to their offering. ... the European medical device legislation. It will explain ... involvement of Notified Bodies, how to choose one ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has ... Legislation (London, UK - November 16-17, 2015)" conference ... EU modules concerning Pharmacovigilance are a major departure in ... Europe . The intention of the course ... examine how they overlap and fit together and what ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... clinical specialty, aimed at improving patient care by ... adjust the dose of drugs for improving outcome. ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2
(Date:9/3/2015)... York, New York (PRWEB) , ... September 03, 2015 , ... ... of the Division of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell Medical ... College. , Dr. Winchell is a nationally renowned expert in care for the critically ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... DiabetesSisters is pleased to announce the additional of Carol Wysham, MD, to their ... board members Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea ...
(Date:9/3/2015)... ... ... A scar is an unavoidable result of incision or injury to the skin. Unsightly as ... itself. The appearance of a scar is dependent on many factors – the size and ... scars fade to near invisibility on their own over a period of months,” says ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... a top review from Clinicians Report of Provo, Utah. The Clinicians Report is ... a selected group of dentists located throughout the U.S. Whiter Image's In-Office whitening ...
(Date:9/3/2015)... ... 2015 , ... James Earl Jones will be hosting an upcoming VOICES IN ... Jones will introduce a segment that discusses why it is important for the workplace ... be fostered in any working environment. , Employers are out billions of dollars year ...
Breaking Medicine News(10 mins):Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2
... relative of the highly pathogenic avian influenza virus (H5N1) ... including// chlorination, ultraviolet (UV) radiation and bacterial digesters. The ... case of the pathways by which the influenza could ... related virus, called H5N2, to see whether a hypothetical ...
... Although it’s our most vital organ, surprisingly little ... That makes it harder to uncover what’s gone ... other brain-associated disorders, and ultimately, it often leaves ... such as Alzheimer’s and Parkinson’s disease, schizophrenia, attention ...
... management of the health service has been revealed by the ... nurses, measly pay rises// and strikes. ,A copy ... reveals that 37000 posts are in danger as the Government ... 2.7 per cent cut in the workforce. ,NHS ...
... circumcision procedure could reduce 50% of the HIV infection rate ... number of Ugandan men seeking it.// , ... reports, out of which nearly half were adults. Less than ... Institutes of Health found that new HIV infections among circumcised ...
... international homeopathy conference is taking place in this Taj ... and eight countries.// ,The four-day meet, which ... AIDS and "other difficult subjects which have proved a ... secretary, told IANS., ,The slogan of the conference ...
... surgical team was led by Dr. Christopher Moir at Minnesota's ... North Dakota// (ND) and now they are on the challenging ... Madysen Fitterer, the twin girls born on Aug. 8 to ... the chest - were both doing very well following the ...
Cached Medicine News:Health News:Avian Flu Unlikely to Spread Through Water Systems 2Health News:Researchers Looking for Genes That Control the Brain 2Health News:A Secret Dossier Predicts Major Changes At NHS, England 2
... A new Transnasal Lacrimal Stent has been ... B. Becker, M.D., the Transnasal Lacrimal Stent addressed ... and other forms of endoscopic DCR. Brought in ... relatively large diameter. Because there is no need ...
...
... electrophysiology system is the Espion. This is an ... wide variety of stimulators for different types of ... ,The Espion system was designed from the ... standard clinical visual function tests, ERG, VEP, PERG, ...
... SIREMOBIL Iso-C3D is based on SIREMOBIL ... the industry. In the intra-operative 3D-Mode, the ... the motorized 190 orbital movement. This allows ... in greater precision during the procedure. This ...
Medicine Products: